A-listers provide a $50M B round to AstraZeneca’s antibiotics spinout Entasis

John Carroll Last summer, AstraZeneca formally spun out its pared-down early-stage antibiotics unit in Waltham, MA, as Entasis Therapeutics, bequeathing a $ 40 million A round for ...

Discount sways U.K. cost gatekeeper on AstraZeneca’s ovarian cancer med Lynparza

Emily Wasserman AstraZeneca scored a victory for its ovarian cancer drug Lynparza, as U.K. cost watchdog the National Institute for Health and Care Excellence did an about-face and ...

AstraZeneca’s gout drug wins faint praise from FDA advisers

Damian Garde A majority of independent FDA advisers recommended approval for AstraZeneca's new gout drug, but not without noting that the treatment's safety profile presents ...

FDA rejects AstraZeneca’s diabetes combo and demands more data

Damian Garde The FDA wants to see more clinical trial data on AstraZeneca's new combination diabetes treatment, the company said, likely delaying a potential launch by more than ...

Safety scare with AstraZeneca’s diabetes drug could shake up the DPP-4 field

Damian Garde The FDA raised some alarming concerns tied to AstraZeneca's Onglyza ahead of a committee meeting to discuss the safety of so-called DPP-4 inhibitors, sounding a worrying ...

AstraZeneca’s Onglyza ‘mortality’ risks noted by FDA reviewers

Eric Palmer FDA staff reviewers have raised serious concerns about the safety of AstraZeneca's Onglyza ahead of an advisory committee review Tuesday, which could result in a recommendation ...

Amgen and AstraZeneca’s psoriasis drug beats blockbuster Stelara in head-to-head trial

John Carroll Amgen and its Big Pharma partner AstraZeneca have roped in another round of promising Phase III plaque psoriasis data for their IL-17 blockbuster contender brodalumab, ...

AstraZeneca’s $2B oncology contender shows promise in prostate cancer

Damian Garde AstraZeneca's ovarian cancer-treating olaparib may also have a beneficial effect on prostate cancer, researchers said, potentially increasing the value of a key drug ...

CEO-hunting Sanofi tried to tempt AstraZeneca’s Soriot: Bloomberg

Tracy Staton Bernstein analyst Tim Anderson figures Sanofi would do well to look outside the company for its new CEO, like AstraZeneca did with its new-ish chief, Pascal Soriot. Well, ...

AstraZeneca’s new antibiotic comes through in Phase III

Damian Garde AstraZeneca's antibiotic combination treatment beat out standard meropenem in treating complicated infections, the company said, setting the table for a near-term shot ...

UPDATED: FDA experts spurn AstraZeneca’s pitch for ovarian cancer drug olaparib

John Carroll AstraZeneca's top investigators took their best case for an accelerated approval of the failed cancer drug olaparib to the FDA's panel of outside experts on Wednesday, ...

In SGLT2 diabetes fight, Lilly’s empagliflozin loss is J&J and AstraZeneca’s gain

Tracy Staton Johnson & Johnson and AstraZeneca will just have to duke it out for share of the market for SGLT2 treatments for diabetes. A potential third competitor from Eli Lilly ...
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS